



D-2939CIP

20

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-112. (Cancelled)

113. (Currently amended) A method of making a soluble botulinum toxin comprising:

expressing a botulinum toxin type A from a prokaryotic expression vector comprising a botulinum toxin type A nucleotide sequence in a prokaryotic host cell wherein the prokaryotic expression vector includes a T7lac promoter ~~weak promoter~~ ~~relative to a T7 promoter~~ thereby making a soluble botulinum toxin type A.

114. (Previously presented) The method of claim 113 wherein the prokaryotic host cell is E. coli.

115. (Previously presented) The method of claim 114 wherein the E. coli is strain BL21 (DE3).


116. (Previously presented) The method of claim 115 wherein a pLys gene is included in the host cell.

117. (Previously presented) The method of claim 116 wherein the pLys gene is plasmid encoded.

118. (Cancelled)

119. (Cancelled)

120. (Cancelled)



D-2939CIP

21

121. (Previously presented) The method of claim 113, wherein the host cell includes a lacIq gene.

122. (Cancelled)

123. (Cancelled)

124. (Previously presented) The method of claim 113, wherein the botulinum toxin nucleotide sequence specifically hybridizes under highly stringent conditions to SEQ ID NO:27.

125-134 (Cancelled)

135. (Cancelled)